[The ISAR-REACT 5 trial: is there a winner between prasugrel and ticagrelor in acute coronary syndromes?]

G Ital Cardiol (Rome). 2020 Mar;21(3):171-174. doi: 10.1714/3306.32764.

[Article in Italian]

Authors

Marco Ferlini¹, Marcello Galvani², Luigi Oltrona Visconti¹

Affiliations

¹ Divisione di Cardiologia, Fondazione IRCCS Policlinico San Matteo, Pavia.
² U.O.C. Cardiologia, Dipartimento Cardiovascolare AUSL Romagna, Ospedale Morgagni, Forlì, e Unità di Ricerca Cardiovascolare, Fondazione Cardiologica Sacco, Forlì.

PMID: 32100728
DOI: 10.1714/3306.32764

No abstract available

Publication types

Editorial

MeSH terms

Acute Coronary Syndrome / drug therapy*
Acute Coronary Syndrome / mortality
Acute Coronary Syndrome / surgery
Aged
Angioplasty, Balloon, Coronary
Cause of Death
Clinical Trials, Phase IV as Topic
Clopidogrel / therapeutic use
Hemorrhage / chemically induced
Humans
Multicenter Studies as Topic
Non-ST Elevated Myocardial Infarction / drug therapy
Platelet Aggregation Inhibitors / adverse effects
Platelet Aggregation Inhibitors / therapeutic use*
Prasugrel Hydrochloride / adverse effects
Prasugrel Hydrochloride / therapeutic use*
Purinergic P2Y Receptor Antagonists / adverse effects
Purinergic P2Y Receptor Antagonists / therapeutic use*
Randomized Controlled Trials as Topic
ST Elevation Myocardial Infarction / drug therapy
Ticagrelor / adverse effects
Ticagrelor / therapeutic use*
Treatment Outcome

Substances

Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Clopidogrel
Prasugrel Hydrochloride
Ticagrelor